MabThera (rituximab) Important Safety Information from Roche Products (Ireland) Limited as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 15/04/2013

 

Problem Or Issue:
Important Safety Information communication from Roche Products (Ireland) Limited on the association of MabThera (rituximab) with Toxic Epidermal Necrolysis and Stevens-Johnson-Syndrome. 

Important Safety Information - MabThera (rituximab)


« Back